Enriched Analgesic Efficacy Studies: An Assessment by Clinical Trial Simulation
The aim of this study was to develop a pain relief model for a cyclooxygenase…
Certara2006 年 4 月 1 日
Kinetic Values for Mechanism-based Enzyme Inhibition: Assessing the Bias Introduced by the Conventional Experimental Protocol
The in vitro characterisation of a mechanism-based enzyme inactivator (MBEI) includes determination of the maximum…
Certara2005 年 11 月 1 日
Model-based Development of Gemcabene, a New Lipid-altering Agent
The purpose of this study was to evaluate the value of model-based, quantitative decision making…
Certara2005 年 10 月 7 日
Model-based Covariate Pharmacokinetic Analysis and Lack of Cortisol Suppression by the New Inhaled Corticosteroid Ciclesonide Using a Novel Cortisol Release Model
Ciclesonide is a novel and effective inhaled corticosteroid for the treatment of asthma that is…
Certara2005 年 9 月 1 日
Therapeutic Benefit of Eletriptan Compared to Sumatriptan for the Acute Relief of Migraine Pain—Results of a Model-based Meta-analysis that Accounts for Encapsulation
A novel model-based meta-analysis was used to quantify the dose-response relationship of sumatriptan and eletriptan…
Certara2005 年 9 月 1 日
Modelling Approaches to Dose Estimation in Children
Most of the drugs on the market are originally developed for adults and dosage selection…
Certara2005 年 6 月 1 日
Techniques: Application of Systems Biology to Absorption, Distribution, Metabolism, Excretion, and Toxicity
It is widely recognized that either predicting or determining the absorption, distribution, metabolism, excretion and…
Certara2005 年 4 月 1 日
Does Neuromuscular Electrical Stimulation Strengthen the Quadriceps Femoris? A Systematic Review of Randomized Controlled Trials
Devices for neuromuscular electrical stimulation (NMES) are increasingly used by individuals without specific injuries and…
Certara2005 年 1 月 1 日
Population Pharmacokinetics of Olmesartan Following Oral Administration of Its Prodrug, Olmesartan Medoxomil: In Healthy Volunteers and Hypertensive Patients
Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly…
Certara2005 年 1 月 1 日
In Silico Simulations to Assess the In Vivo Consequences of In Vitro Metabolic Drug-drug Interactions
Recently, metabolic drug-drug interactions (M-DDI) have raised some high-profile problems in drug development resulting in restricted use, withdrawal…
Certara2004 年 12 月 1 日
